Arovella Therapeutics Ltd
ASX:ALA

Watchlist Manager
Arovella Therapeutics Ltd Logo
Arovella Therapeutics Ltd
ASX:ALA
Watchlist
Price: 0.18 AUD -5.26% Market Closed
Market Cap: 189.3m AUD
Have any thoughts about
Arovella Therapeutics Ltd?
Write Note

Relative Value

ALA doesn't have a meaningful market cap.

The Relative Value of one ALA stock under the Base Case scenario is 0.001 AUD. Compared to the current market price of 0.18 AUD, Arovella Therapeutics Ltd is Overvalued by 100%.

Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.

ALA Relative Value
Base Case
0.001 AUD
Overvaluation 100%
Relative Value
Price
Worst Case
Base Case
Best Case

Valuation Multiples

vs History
0
vs Industry
1
Median 3Y
132.6
Median 5Y
62.6
Industry
2.6
vs History
vs Industry
Median 3Y
-4.1
Median 5Y
-5.7
Industry
22.3
Forward
-17.8
vs History
vs Industry
Median 3Y
-6.4
Median 5Y
-8.2
Industry
17.5
vs History
vs Industry
Median 3Y
-5.5
Median 5Y
-8.2
Industry
24.8
vs History
12
vs Industry
1
Median 3Y
7
Median 5Y
3.1
Industry
2.1
vs History
0
vs Industry
0
Median 3Y
120.7
Median 5Y
45.6
Industry
2.7
vs History
1
vs Industry
0
Median 3Y
188.5
Median 5Y
67.7
Industry
5.3
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.9
Industry
13.4
Forward
-14.7
vs History
vs Industry
Median 3Y
-3.4
Median 5Y
-4.9
Industry
16.8
Forward
-16.4
vs History
vs Industry
Median 3Y
-4.8
Median 5Y
-7.4
Industry
15.9
vs History
vs Industry
Median 3Y
-4.4
Median 5Y
-6.6
Industry
18.5
vs History
vs Industry
3
Median 3Y
4.4
Median 5Y
1.6
Industry
1.9

Multiples Across Competitors

ALA Competitors Multiples
Arovella Therapeutics Ltd Competitors

All Multiples
P/S
P/E
EV/EBITDA
EV/EBIT
All Countries
Close
Market Cap P/S P/E EV/EBITDA EV/EBIT
AU
Arovella Therapeutics Ltd
ASX:ALA
189.1m AUD 1 214.2 -21.6 -20.2 -20.2
JP
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
776 550.9T JPY 4 211 733 -5 347 888.9 -5 459 134.4 -5 046 864.6
US
Eli Lilly and Co
NYSE:LLY
788.6B USD 20.3 107.4 53.8 60.2
UK
Dechra Pharmaceuticals PLC
LSE:DPH
440.4B GBP 578.3 -15 783.5 3 846.3 17 702.3
DK
Novo Nordisk A/S
CSE:NOVO B
3.4T DKK 13.1 37.5 25 28.7
US
Johnson & Johnson
NYSE:JNJ
384.8B USD 4.4 26.2 12.6 16.5
US
Merck & Co Inc
NYSE:MRK
259.4B USD 4.2 18.9 12.8 15.8
CH
Roche Holding AG
SIX:ROG
213.6B CHF 3.6 18.6 10.4 12.4
UK
AstraZeneca PLC
LSE:AZN
171.2B GBP 4.5 34.3 170.5 255.6
CH
Novartis AG
SIX:NOVN
183.5B CHF 4.3 13.1 10.4 15.4
US
Pfizer Inc
NYSE:PFE
160.4B USD 2.7 37.7 11 16.7
P/E Multiple
Earnings Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average P/E: 36.7
Negative Multiple: -21.6
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 347 888.9 N/A
US
Eli Lilly and Co
NYSE:LLY
107.4
454%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
Negative Multiple: -15 783.5 N/A
DK
Novo Nordisk A/S
CSE:NOVO B
37.5
89%
US
Johnson & Johnson
NYSE:JNJ
26.2
-22%
US
Merck & Co Inc
NYSE:MRK
18.9
7 426%
CH
Roche Holding AG
SIX:ROG
18.6
30%
UK
AstraZeneca PLC
LSE:AZN
34.3
175%
CH
Novartis AG
SIX:NOVN
13.1
19%
US
Pfizer Inc
NYSE:PFE
37.7
712%
EV/EBIT Multiple
EBIT Growth
AU
Arovella Therapeutics Ltd
ASX:ALA
Average EV/EBIT: 2 013.7
Negative Multiple: -20.2
N/A
JP
N
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
Negative Multiple: -5 046 864.6 N/A
US
Eli Lilly and Co
NYSE:LLY
60.2
212%
UK
Dechra Pharmaceuticals PLC
LSE:DPH
17 702.3
675%
DK
Novo Nordisk A/S
CSE:NOVO B
28.7
85%
US
Johnson & Johnson
NYSE:JNJ
16.5
29%
US
Merck & Co Inc
NYSE:MRK
15.8
695%
CH
Roche Holding AG
SIX:ROG
12.4
27%
UK
AstraZeneca PLC
LSE:AZN
255.6
131%
CH
Novartis AG
SIX:NOVN
15.4
54%
US
Pfizer Inc
NYSE:PFE
16.7
63%

See Also

Discover More
Back to Top